At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 26 target
Drug / intervention
Blinatumomab Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Concurrent Inotuzumab and Subcutaneous Blinatumomab in Adult Patients With B-cell Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Blinatumomab Injection for B-cell Acute Lymphoblastic Leukemia and 2 related conditions. Not yet recruiting, targeting 26 participants across 1 site.
Detailed Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
Phase 2Not Yet Recruiting
2026202720282029
First PostedJan 2026
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionJan 2029
First PostedJan 2, 2026
Enrollment StartJun 1, 2026
Primary CompletionJan 1, 2029
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 6 months agoPrimary completion in 2.5 years
Interventions
Blinatumomab Injectiondrug
Blinatumomab given via subcutaneous injection